Announcement under Regulation 30-Agenda items Approved by Shareholders at the Annual General Meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sandu Pharmaceuticals held its 40th AGM on 30th September 2025, with voting results announced on 1st October 2025. Shareholders approved four key items: ratification of remuneration for M/s Shekhar Joshi & Co as Cost Auditor for FY 2025-26; appointment of M/s Swapnil J Dixit & Associates as Secretarial Auditor for a five-year term from FY 2025-26 to FY 2029-30; approval of a material related party transaction with Sandu Brothers Private Limited; and continuation of Shri. Vijay Kajarekar as Chief Financial Officer even after he turns 70 in 2026. The meeting concluded at 5:24 pm.
These are routine governance and compliance approvals with no major strategic change expected. The related party transaction approval with Sandu Brothers Pvt Ltd is the only item investors should monitor, as it signals continued intra-group dealings. CFO continuity beyond retirement age suggests management stability.